GlassScriptPhysician profile
Matthew James Sabo
NPI 1447218706
$400.13
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2021: $137 · 2022: $16.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $149.86 | 2019-2021 | |
| Melinta Therapeutics, LLC | $81.12 | 2019 | |
| Integra Lifesciences Corporation | $41.14 | 2019 | |
| Merck Sharp & Dohme LLC | $30.34 | 2019 | |
| Bioventus LLC | $19.82 | 2019 | |
| Pfizer INC. | $17.29 | 2019 | |
| Biotissue Holdings INC. | $17.00 | 2021 | |
| Nabriva Therapeutics, Plc | $16.61 | 2022 | |
| 3m Company | $15.41 | 2019 | |
| Tactile Systems Technology INC | $11.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.